Quantitative molecular evaluation of minimal residual disease in patients with chronic lymphocytic leukemia: efficacy of in vivo purging by alemtuzumab (Campath-1H)
- PMID: 15314547
- DOI: 10.1097/00002371-200409000-00007
Quantitative molecular evaluation of minimal residual disease in patients with chronic lymphocytic leukemia: efficacy of in vivo purging by alemtuzumab (Campath-1H)
Abstract
Although novel therapies for chronic lymphocytic leukemia have resulted in higher hematologic response rates, the complete eradication of disease rarely occurs. Alemtuzumab (Campath-1H) seems to be extremely effective in this role in pretreated patients. The authors used a molecular semiquantitative polymerase chain reaction (PCR) method to assess the ability of alemtuzumab to induce PCR negativity in eight patients pretreated with fludarabine. IgH rearrangement was coamplified with a housekeeping gene and fluorescent PCR products were analyzed on a DNA automatic sequencer. Each patient was evaluated at diagnosis, after fludarabine, and after Campath-1H. The median interval between the last therapy course with fludarabine and the start of Campath-1H was 14 weeks. Patients received subcutaneous doses up to 10 mg, three times a week, for 12 weeks, with a median dose of 190 mg. After six cycles with fludarabine, only one patient (12.5%) achieved molecular remission, and in three other patients IgH levels decreased by 0.5 to 1 log. At the beginning of Campath-1H administration, all patients were PCR positive, including the one previously found to be negative. At the end of treatment, five patients achieved molecular remission (62.5%), four of them within 1 month after the end of therapy. Seventy-two percent of responses, with 43% of complete responses, were documented on bone marrow smears. A significant reduction of lymph node and spleen diameters was noted in 50% and 33% of patients, respectively. Four patients showed grade 2 skin reaction at the site of the subcutaneous injection and grade 1 or 2 fever. Two patients developed neutropenia (grade 2 and 3) and two hemolytic episodes. Three patients showed cytomegalovirus and one herpes zoster and Epstein-Barr virus reactivation. These results show that Campath-1H represents an efficacious in vivo purging tool with a safe profile.
Copyright 2004 Lippincott Williams & Wilkins
Similar articles
-
Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine.Haematologica. 2002 Jul;87(7):695-700; discussion 700. Haematologica. 2002. PMID: 12091119 Clinical Trial.
-
Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia.J Clin Oncol. 2006 May 20;24(15):2337-42. doi: 10.1200/JCO.2005.04.6037. Epub 2006 Apr 17. J Clin Oncol. 2006. PMID: 16618945 Clinical Trial.
-
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.Blood. 2002 May 15;99(10):3554-61. doi: 10.1182/blood.v99.10.3554. Blood. 2002. PMID: 11986207 Clinical Trial.
-
Eradication of minimal residual disease with alemtuzumab in B-cell chronic lymphocytic leukemia (B-CLL) patients: the need for a standard method of detection and the potential impact of bone marrow clearance on disease outcome.Cancer Invest. 2005;23(6):488-96. doi: 10.1080/07357900500201418. Cancer Invest. 2005. PMID: 16203656 Review.
-
Clinical effects of alemtuzumab (Campath-1H) in B-cell chronic lymphocytic leukemia.Med Oncol. 2002;19 Suppl:S21-6. doi: 10.1385/mo:19:2s:s21. Med Oncol. 2002. PMID: 12180488 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources